共 241 条
[11]
Hyndman KA(2014)Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1 Hypertension (Dallas, Tex: 1979) 64 296-304
[12]
Dhaun N(2017)Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis Blood Press 26 139-149
[13]
Southan C(2016)From bosentan (Tracleer(R)) to macitentan (Opsumit(R)): the medicinal chemistry perspective Bioorg Med Chem Lett 26 3381-3394
[14]
Kohan DE(2017)Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET) Kidney Int Rep 2 654-664
[15]
Pollock JS(1998)The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators N Engl J Med 338 784-790
[16]
Pollock DM(2002)Darusentan: an effective endothelin Am J Hypertens 15 583-589
[17]
Webb DJ(2009) receptor antagonist for treatment of hypertension Lancet (London, England) 374 1423-1431
[18]
Maguire JJ(2010)A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial Hypertension (Dallas, Tex: 1979) 56 806-807
[19]
Davenport AP(2011)DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension Eur J Clin Pharmacol 67 977-984
[20]
Kiowski W(2015)Macitentan: entry-into-humans study with a new endothelin receptor antagonist Curr Opin Pharmacol 21 25-34